These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 28795368)

  • 1. The 9th Biennial Conference on Signal Detection and Interpretation in Pharmacovigilance.
    Osborne V; Shakir SAW
    Drug Saf; 2018 Jan; 41(1):139-141. PubMed ID: 28795368
    [No Abstract]   [Full Text] [Related]  

  • 2. Modernising vaccine surveillance systems to improve detection of rare or poorly defined adverse events.
    Chandler RE
    BMJ; 2019 May; 365():l2268. PubMed ID: 31151960
    [No Abstract]   [Full Text] [Related]  

  • 3. French pharmacovigilance: Missions, organization and perspectives.
    Vial T
    Therapie; 2016 Apr; 71(2):143-50. PubMed ID: 27080832
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Communication of findings in pharmacovigilance: use of the term "signal" and the need for precision in its use.
    Hauben M; Reich L
    Eur J Clin Pharmacol; 2005 Jul; 61(5-6):479-80. PubMed ID: 15991039
    [No Abstract]   [Full Text] [Related]  

  • 5. [Editorial: adverse drug reactions].
    Taegtmeyer AB
    Ther Umsch; 2015 Dec; 72(11-12):667. PubMed ID: 26654808
    [No Abstract]   [Full Text] [Related]  

  • 6. Pharmacovigilance workflow in Europe and Italy and pharmacovigilance terminology.
    Baldo P; Francescon S; Fornasier G
    Int J Clin Pharm; 2018 Aug; 40(4):748-753. PubMed ID: 30094557
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Fifty years of pharmacovigilance - Medicines safety and public health.
    Laporte JR
    Pharmacoepidemiol Drug Saf; 2016 Jun; 25(6):725-32. PubMed ID: 26799344
    [No Abstract]   [Full Text] [Related]  

  • 8. [Adverse drug reaction - Definitions, risk factors and pharmacovigilance].
    Krähenbühl S
    Ther Umsch; 2015 Dec; 72(11-12):669-71. PubMed ID: 26654809
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Towards Drug Safety Surveillance and Pharmacovigilance: Current Progress in Detecting Medication and Adverse Drug Events from Electronic Health Records.
    Liu F; Jagannatha A; Yu H
    Drug Saf; 2019 Jan; 42(1):95-97. PubMed ID: 30649734
    [No Abstract]   [Full Text] [Related]  

  • 10. Promoting and Protecting Public Health: How the European Union Pharmacovigilance System Works.
    Santoro A; Genov G; Spooner A; Raine J; Arlett P
    Drug Saf; 2017 Oct; 40(10):855-869. PubMed ID: 28735357
    [TBL] [Abstract][Full Text] [Related]  

  • 11. EUROmediCAT Recommendations for European Pharmacovigilance concerning safety of medication use in pregnancy.
    EUROmediCAT Steering Group
    Pharmacoepidemiol Drug Saf; 2015 Oct; 24 Suppl 2():3-7. PubMed ID: 26395593
    [No Abstract]   [Full Text] [Related]  

  • 12. Filling quality of the reports of adverse drug reactions received at the Pharmacovigilance Centre of São Paulo (Brazil): missing information hinders the analysis of suspected associations.
    Ribeiro A; Lima S; Zampieri ME; Peinado M; Figueras A
    Expert Opin Drug Saf; 2017 Dec; 16(12):1329-1334. PubMed ID: 28817316
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Harmonisation in pharmacovigilance.
    Edwards IR; Biriell C
    Drug Saf; 1994 Feb; 10(2):93-102. PubMed ID: 8011183
    [No Abstract]   [Full Text] [Related]  

  • 14. Pharmacovigilance in Europe.
    Johnson CL; Hutchinson JA
    Transplantation; 2015 Aug; 99(8):1542-3. PubMed ID: 26308299
    [No Abstract]   [Full Text] [Related]  

  • 15. Safety Concerns Reported by Patients Identified in a Collaborative Signal Detection Workshop using VigiBase: Results and Reflections from Lareb and Uppsala Monitoring Centre.
    Watson S; Chandler RE; Taavola H; Härmark L; Grundmark B; Zekarias A; Star K; van Hunsel F
    Drug Saf; 2018 Feb; 41(2):203-212. PubMed ID: 28933055
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Encouraging spontaneous reporting of adverse effects.
    Prescrire Int; 2015 Feb; 24(157):53. PubMed ID: 25802925
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Use of measures of disproportionality in pharmacovigilance: three Dutch examples.
    Egberts AC; Meyboom RH; van Puijenbroek EP
    Drug Saf; 2002; 25(6):453-8. PubMed ID: 12071783
    [TBL] [Abstract][Full Text] [Related]  

  • 18. An Evaluation of Indian Consumers' Reporting of Suspected Adverse Drug Reactions with a Designated Reporting Form.
    Rehan HS; Sah R; Gupta A; Nagar P
    Curr Drug Saf; 2017; 12(1):51-56. PubMed ID: 27188794
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Towards on-line ADR detection: an innovative data cube-based approach.
    Lin WY; Du JW
    Stud Health Technol Inform; 2013; 192():1218. PubMed ID: 23920992
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A Pharmacovigilance Signaling System Based on FDA Regulatory Action and Post-Marketing Adverse Event Reports.
    Hoffman KB; Dimbil M; Tatonetti NP; Kyle RF
    Drug Saf; 2016 Jun; 39(6):561-75. PubMed ID: 26946292
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.